Migraine biotech TriGemX to go public via SPAC merger with $246M in proceeds
What's the deal? TriGemX Bio has agreed to merge with TCGX Acquisition Corp.Dealroom has a profile for this one. Try Dealroom →, a special purpose acquisition company (SPAC), to become a Nasdaq-listed company under the ticker "TGEM." The combined company, to be named TriGemX Bio, Inc., expects about $246 million in gross proceeds before transaction costs and assuming no redemptions.
How is it structured? Proceeds combine roughly $86 million held in TCGX's trust with a concurrent $160 million private investment in public equity (PIPE) financing at $10.00 per share. Investors include TCGX, Viking Global InvestorsDealroom has a profile for this one. Try Dealroom →, ADAR1 Capital ManagementDealroom has a profile for this one. Try Dealroom →, BVF PartnersDealroom has a profile for this one. Try Dealroom →, Samsara BioCapitalDealroom has a profile for this one. Try Dealroom →, and Vianti CapitalDealroom has a profile for this one. Try Dealroom →. TriGemX shareholders will roll 100% of their equity into the combined company and receive no cash.
What's the endgame? TriGemX is developing elismetrep, an investigational oral TRPM8 blocker positioned as a potential first-in-class acute migraine treatment. The capital is intended to fund Phase 3 trials, support an application in migraine prevention, and prepare for a potential US launch.
Why now? "With the anticipated proceeds from this transaction, TriGemX will be positioned to fully fund the Phase 3 development of elismetrep," said chief executive officer Jeff Goater. The deal gives a late-stage, single-drug biotech a route to public-market funding ahead of its main value catalyst.
What could go wrong? The drug's first-in-class label is not evidence of efficacy; elismetrep has shown encouraging Phase 2b results but remains unapproved, with first Phase 3 data expected mid-2027. The merger, slated to close in the first quarter of 2027, is subject to shareholder approvals and customary conditions, so both financing certainty and clinical risk remain.
The signal: SPAC mergers are serving again as a path for pre-revenue biotechs to tap public markets before their science is proven. For investors, the bet rests on a single drug whose decisive trial results still lie ahead.
Read more: business.am-news.com
Image credit: Generated with Gemini
